Botulinum neurotoxin type A · SINGLE PROTEIN · Clostridium botulinum
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Botulinum neurotoxin type A shows clinical signal disease relevance led by commensal Clostridium infectious disease. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P0DPI0. Start with commensal Clostridium infectious disease, then reuse UniProt P0DPI0 as the stable protein anchor across project notes and exports.
Start with commensal Clostridium infectious disease, then reuse UniProt P0DPI0 as the stable protein anchor across project notes and exports.
Botulinum neurotoxin type A shows clinical signal disease relevance led by commensal Clostridium infectious disease. 1 linked drug remains visible in the same block.
Start review with commensal Clostridium infectious disease because it currently carries clinical signal support. Linked drugs include GS-CDA1. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyBotulinum neurotoxin type A
Review this target as Botulinum neurotoxin type A, mapped to UniProt P0DPI0. Sequence length is 1296 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Botulinum neurotoxin type A as ChEMBL target CHEMBL5192, mapped to UniProt P0DPI0. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Botulinum neurotoxin type A is the right protein anchor across sources, using UniProt P0DPI0 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why commensal Clostridium infectious disease is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Botulinum neurotoxin type A |
| Target Type | SINGLE PROTEIN |
| Organism | Clostridium botulinum |
| UniProt | P0DPI0 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Botulinum neurotoxin type A |
| UniProt Accession | P0DPI0 |
| Component Type | Protein |
| Sequence Length | 1296 aa |
Botulinum neurotoxin type A
Review this target as Botulinum neurotoxin type A, mapped to UniProt P0DPI0. Sequence length is 1296 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Botulinum neurotoxin type A shows clinical signal disease relevance led by commensal Clostridium infectious disease.
Start review with commensal Clostridium infectious disease because it currently carries clinical signal support. Linked drugs include GS-CDA1. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3627987 | 7.91 | Ki | 12.3 | Preclinical |
| CHEMBL42527 | 7.58 | IC50 | 26.0 | Preclinical |
| CHEMBL2336714 | 7.57 | Ki | 27.0 | Preclinical |
| CHEMBL2336715 | 7.57 | Ki | 27.0 | Preclinical |
| CHEMBL2336714 | 7.52 | IC50 | 30.0 | Preclinical |
| CHEMBL2336715 | 7.4 | IC50 | 40.0 | Preclinical |
| CHEMBL4474592 | 7.39 | Ki | 41.0 | Preclinical |
| CHEMBL3112881 | 7.11 | Ki | 77.0 | Preclinical |
| CHEMBL3264512 | 6.99 | Ki | 103.0 | Preclinical |
| CHEMBL2336713 | 6.89 | Ki | 130.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 152 | 352 | 5.4 |
| assay format | 44 | 112 | 5.2 |
| cell-based format | 6 | 3 | 4.4 |
| subcellular format | 2 | 0 | — |